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ABSTRACT
Objective HCV is a major cause of chronic liver
disease worldwide, but the role of neutralising
antibodies (nAbs) in its natural history remains poorly
deﬁned. We analysed the in vivo role of hypervariable
region 1 (HVR1) for HCV virion properties, including nAb
susceptibility.
Design Analysis of HCV from human liver chimeric
mice infected with cell-culture-derived prototype
genotype 2a recombinant J6/JFH1 or HVR1-deleted
variant J6/JFH1ΔHVR1 identiﬁed adaptive mutations,
which were analysed by reverse genetics in Huh7.5 and
CD81-deﬁcient S29 cells. The increased in vivo genomic
stability of the adapted viruses facilitated ex vivo density
analysis by ultracentrifugation and in vivo neutralisation
experiments addressing the role of HVR1.
Results In vivo, J6/JFH1 and J6/JFH1ΔHVR1 depended
on single substitutions within amino acids 867–876 in
non-structural protein, NS2. The identiﬁed A876P-
substitution resulted in a 4.7-fold increase in genomic
stability. In vitro, NS2 substitutions enhanced infectivity
5–10-fold by increasing virus assembly. Mouse-derived
mJ6/JFH1A876P and mJ6/JFH1ΔHVR1/A876P viruses
displayed similar heterogeneous densities of 1.02–1.1
g/mL. Human liver chimeric mice loaded with
heterologous patient H (genotype 1a) immunoglobulin
had partial protection against mJ6/JFH1A876P and
complete protection against mJ6/JFH1ΔHVR1/A876P.
Interestingly, we identiﬁed a putative escape mutation,
D476G, in mJ6/JFH1A876P. This mutation in hypervariable
region 2 conferred 6.6-fold resistance against H06 IgG in
vitro.
Conclusions The A876P-substitution bridges in vitro
and in vivo studies using J6/JFH1-based recombinants.
We provide the ﬁrst in vivo evidence that HVR1 protects
cross-genotype conserved HCV neutralisation epitopes,
which advocates the possibility of using HVR1-deleted
viruses as vaccine antigens to boost broadly reactive
protective nAb responses.
INTRODUCTION
Approximately 180 million people worldwide are
chronically infected with HCV, with increased risk
of developing liver cirrhosis and hepatocellular car-
cinoma.1 2 Despite recent introduction of
direct-acting antivirals, a vaccine is urgently needed
to control HCV worldwide3; there are ∼4 million
new infections annually. HCV is a positive single-
Signiﬁcance of this study
What is already known on this subject?
▸ Little is known about the comparable ﬁtness of
HCV recombinants in vitro (cell culture) versus
in vivo (mouse models).
▸ Plasma-derived HCV particles display low
buoyant density through association with
lipoproteins and the virus is able to persist in
patients in the presence of potentially
neutralising antibodies.
▸ Hypervariable region 1 (HVR1)-deleted HCV has
altered physiochemical properties (ie, high
density) in vitro.
▸ HVR1 of HCV protects the virus against
neutralising antibodies in vitro.
What are the new ﬁndings?
▸ Mutations within the HCV gene, NS2, confer in
vivo stability of a cell culture infectious HCV
recombinant ( J6/JFH1), thus bridging the gap
between in vitro and in vivo studies.
▸ Identiﬁcation of adaptive NS2 mutations that
might aid in the production of sufﬁcient
quantities of culture derived HCV for
whole-virus vaccine approaches.
▸ HVR1 protects cross-genotype reactive HCV
epitopes in vivo, thus indicating that
HVR1-mediated antibody resistance is a
contributor to viral persistence in infected
patients.
▸ In vivo, HVR1-deleted HCV particles have the
same low-density proﬁle as unmodiﬁed
particles.
▸ Hypervariable region 2 of HCV may contribute
to persistence by providing escape from
neutralising antibodies.
How might it impact on clinical practice in
the foreseeable future?
▸ The study provides much needed in vivo data
on the virological determinants of HCV
neutralisation and control, with implications for
vaccine development.
▸ The development of an HCV vaccine presents
major challenges, but is the only effective way
to curtail the HCV global heath impact in the
foreseeable future.
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stranded RNA virus of the Flaviviridae family, encoding the
structural proteins Core and envelope proteins 1 and 2 (E1 and
E2), p7 and non-structural (NS) proteins 2, 3, 4A, 4B, 5A and
5B.4 HCV is stratiﬁed into seven major genotypes with many
clinically relevant subtypes,5 and it circulates in infected indivi-
duals as a heterogeneous quasispecies with implications for
effectiveness of immune responses.6
The genotype 2a HCV isolate, JFH1, shown to infect Huh7
hepatoma cell lines,7 has allowed in-depth probing of the virus
life cycle.8 Low in vitro infectivity of JFH1 was initially over-
come by development of the JFH1-based intragenotypic recom-
binant, J6/JFH1, in which core-NS2 had been replaced with
corresponding genes of another genotype 2a isolate, J6.9 10
Additional in vivo studies were made possible by the small
animal model, urokinase-type plasminogen activator-severe
combined immunodeﬁciency mice with human liver xenografts
(human liver chimeric mice), which is a robust HCV infection
model.11–13 Culture-derived J6/JFH1 infected human liver chi-
meric mice and chimpanzees;14 15 we conﬁrmed genomic stabil-
ity of J6/JFH1 in vitro.16 17 However, in vivo genomic stability
of this ﬁrst high-titre HCV recombinant remains unexplored
and could represent a virus proliferation bottleneck complicat-
ing the interpretation of in vivo studies.
The role of neutralising antibodies (nAbs) in resolving acute
HCV infection remains incompletely understood.18 Although
some patient studies suggest that the rapid induction of broadly
reactive nAbs is associated with viral clearance,19 20 the implica-
tions for immunotherapy and vaccine development remain
unclear. Speciﬁcally, the envelope proteins of HCV could be
immunologically distinct across genotypes, or even subtypes,
resulting in limited antibody cross-reactivity.21 Although cross-
reactivity of human sera from patients with chronic HCV has
been reported in vitro17 and in vivo,22 no in vivo neutralisation
data on hard-to-neutralise strains, such as 2a strain J6,17 23 was
reported. We previously showed that the E2 27 amino acid
motif hypervariable region 1 (HVR1), found to be non-essential
for in vivo infectivity,24 25 protected the virus from neutralisa-
tion at cross-genotype conserved epitopes in vitro.25 However,
differences in HCV properties between culture-derived and in
vivo derived HCV particles could greatly inﬂuence such ﬁnd-
ings.14 In vitro, HVR1-deleted infectious particles displayed a
shift in density from a 1.01 to 1.1 g/mL range to a single peak
at ∼1.1 g/mL.25
To address the importance of HVR1 for HCV neutralisation
protection in vivo, we adapted the HCV recombinant, J6/JFH1,
and the HVR1-deleted variant J6/JFH1ΔHVR1, to yield consist-
ent high titres during in vivo infections of human liver chimeric
mice and assayed their physiochemical properties. These in vivo
derived, fully adapted and physiochemically similar viruses with
and without HVR1 were used to address whether HVR1 pro-
tects HCVagainst cross-genotype reactive nAbs in vivo.
MATERIALS AND METHODS
Plasmids
We used plasmids encoding the genotype 2a recombinant J6/
JFH1 and the HVR1-deleted variant J6/JFH1ΔHVR1.
9 25 Point
mutations were inserted by conventional cloning techniques,
and the HCV sequence of ﬁnal maxipreps was conﬁrmed
(Macrogen).
Cell culturing
Huh7.5 human hepatoma cells and Huh7-derived S29 cells26
(with low CD81 expression conferring non-susceptibility to
HCV) were grown in Dulbecco’s modiﬁed Eagle’s medium
supplemented with 10% fetal bovine serum and antibiotics.
Culturing and infections of cells with HCV were done as
described.16 Infected cultures were evaluated every second day
by NS5A-speciﬁc immunostaining. Transfections of cells with in
vitro transcribed HCV RNA using Lipofectamine2000 (Life
Technologies) were carried out for 4 h in OPTIMEM, trypsi-
nised and reseeded at 100 000 cells/well in 24-well plates, while
also plating four wells in slides for HCV-speciﬁc immunostain-
ing to monitor viral spread. Supernatant collection and
HCV-speciﬁc cell staining was carried out at days 1, 2, 3 and 4
post transfection.16 S29 cell transfections and evaluation of
intracellular Core and infectivity as well as extracellular Core
and infectivity were carried out as described.27 Brieﬂy, intracel-
lular HCV was released by ﬁve freeze/thaw cycles and intracellu-
lar Core was extracted in cold RIPA buffer supplemented with
protease inhibitors. Intracellular and extracellular samples were
analysed for Core (Abbott ARCHITECT HCV Ag assay) and
HCV infectivity titres. Direct HCV open reading frame (ORF)
sequencing of viruses recovered from culture supernatants was
done by RT-nested PCR procedures.16
Human liver chimeric mouse infections
Animal studies using human liver chimeric mice engrafted with
human hepatocytes were performed at Ghent University, with
protocols approved by the local Animal Ethics Committee. Mice
were prepared as described,12 28 and inoculated by intraperito-
neal injection of 104 50% tissue culture infectious dose
(TCID50) or focus forming units (FFUs) of culture-derived HCV,
or 104 IU HCV RNA of mouse-derived HCV. Mouse liver
repopulation by human hepatocytes was conﬁrmed 2–3 days
pre-inoculation by measuring human albumin plasma levels.
Human polyclonal IgG levels in the animals were measured by
an in-house ELISA as described.29 Sequencing the HCV ORF of
viruses recovered from plasma or serum was performed as
above, except that random hexamers were used in reverse tran-
scription with Superscript II (Invitrogen). Analysing the entire
HCV envelope protein sequence of HCV from in vivo-derived
serum pools was done by RT-PCR and clonal analysis, and sub-
sequent direct sequencing of any positions with >20% sequence
variation. Cell culture experiments using mouse plasma were
done with 5 IU/mL heparin.
Equilibrium density gradient centrifugation
Step gradients were made as described.25 Brieﬂy, iodixanol at
40%, 30%, 20% and 10% (Optiprep, Axis-Shield) was layered
and left upright for 24 h at 4°C for formation of semi-
continuous gradients. Samples were added to the top of the
gradients and these were spun at 35 000 rpm (∼151 000×the
Relative Centrifugal Force) for 18 h at 4°C. Subsequently, 1 mL
gradient fractions were harvested from the bottom and 700 mL
were weighed to calculate fraction densities. Fractions were
titrated for infectivity and HCV RNA at 1:10 dilutions as
described below.
HCV infectivity and RNA titration of mouse and cell
culture-derived samples
Initially cell culture supernatant infectivity titres were deter-
mined using limiting dilution (10-fold) TCID50 assays with six
replicates.16 Subsequently, titrations were performed in tripli-
cates using an assay allowing automated counting of FFU using
ImmunoSpot Series 5 UVAnalyzer.30 HCV RNA titres of mouse
and cell culture samples were measured either by Roche COBAS
AmpliPrep/COBAS TaqMan HCV test or in house qPCR.16
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In vitro neutralisation
We used puriﬁed polyclonal IgG antibodies (H06 IgG) isolated
from genotype 1a chronic-phase patient H plasma collected in
2006,22 31 as well as monoclonal antibodies AR3A, AR4A and
AR5A with the b6 control antibody.32 33 We plated 6×103
Huh7.5 cells/well into poly-D-lysine-coated 96-well plates (96
Well Optical Bottom Plates, Nunc). The following day four
replicates of culture-derived HCV (yielding FFU/well of
between 45 and 170 counts in the virus-only controls) were
incubated 1 h at 37°C with an IgG dilution series and subse-
quently incubated with cells along with eight replicates of virus
without IgG. The infected cells were washed after 3 h incuba-
tion with the virus/IgG or virus only, and following an add-
itional 45 h the cells were ﬁxed and HCV-speciﬁc
immunostaining was performed.16 The percent neutralisation
was calculated by relating FFU counts to the mean of eight repli-
cates incubated with virus only. Neutralisation data were ana-
lysed as dose–response curves using GraphPad Prism V.4.03.
In vivo neutralisation
The methodology was previously described in detail.34 Here, all
mice were loaded with 1 mg/g body weight of puriﬁed H06 IgG
or with puriﬁed control IgG isolated from HCV-negative
healthy volunteers (Irrelevant IgG). In prior homologous chal-
lenge experiments, the 1 mg/g IgG dose appeared to give better
protection than 0.2 mg/g34; due to the limited availability of
H06 IgG, it was not feasible to use higher doses. Three days
after infusion with the antibodies, the animals were injected
with a 100% infectious dose of in vivo derived HCV (104 IU/
mouse). Both the antibody and the virus were injected
intraperitoneally. We previously found that 3 days after injection
an insigniﬁcant amount of antibody was retained in the periton-
eal cavity.34
RESULTS
Human liver chimeric mouse inoculations with
culture-derived prototype HCV recombinants J6/JFH1 and J6/
JFH1ΔHVR1
Lindenbach et al14 demonstrated that the genotype 2a intragen-
otypic HCV recombinant, J6/JFH1, infected human liver chi-
meric mice and chimpanzees. We subsequently showed that J6/
JFH1 and J6/JFH1ΔHVR1 infected human liver chimeric mice
(B156 and B150R, respectively) without acquiring envelope
mutations.25
HCV infection of B156 and B150R were studied among seven
inoculations in which three and four mice were inoculated with
104 TCID50 of culture-derived J6/JFH1 (B156, B139 and K888)
or J6/JFH1ΔHVR1 (B150R, K826, K890R and B139L), respect-
ively. During a 4-week follow-up, two and three mice infected
with J6/JFH1 and J6/JFH1ΔHVR1, respectively, developed infec-
tions with HCV genome titres >105 IU/mL (ﬁgure 1A, B).
Mouse B139L had HCV RNA titres below the assay detection
limit of <103 IU/mL (ﬁgure 1B) and K888 displayed HCV RNA
titres between 104 and 105 IU/mL (ﬁgure 1A).
Sequence analysis of HCV recovered from robust in vivo
infections identiﬁed coding mutations within a short region
of NS2
We extracted HCV RNA from high-titre mouse samples (week
2, K826 and B139; week 3, K890R and B150R; and week 4,
Figure 1 Inoculation of human liver chimeric mice with culture-derived HCV recombinant J6/JFH1 with and without hypervariable region 1 (HVR1).
Mice were inoculated with similar doses of culture-derived HCV recombinants (A) J6/JFH1, (B) J6/JFH1ΔHVR1, (C) J6/JFH1A876P and (D) J6/JFH1ΔHVR1/
A876P. HCV RNA titres were monitored on animal plasma or serum samples for 4 weeks post inoculation. Limit of HCV RNA detection was 1000 IU/
mL.*The mouse died following sampling at the indicated timepoint. # No HCV RNA analyses were performed on later samples from this mouse.
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Table 1 Sequence analysis of coding changes in J6/JFH1 and derived viruses from mouse samples and in vitro passages of mouse samples.
HCV gene Core Core E2 E2 E2 NS2 NS2 NS2 NS2 NS2 NS2 NS3 NS5A NS5A NS5A NS5B
Nucleotide number and type
J6/JFH1 position 572 621 1641 1679 2528 2952 2955 2964 2965 2978 3051 4306 7069 7164 7389 7697
H77 abs. ref. (AF009606) 573 622 1642 1680 2517 2941 2944 2953 2954 2967 3040 4295 7070 7165 7390 7632
Nucleotide of J6/JFH1 A C A T T G G A T G A C G T A A
J6/JFH1 Infected human liver chimeric mouse samples
B139—serum (ex vivo) • T/C • • • • • A/g A/t • • • • T/A • •
B139—1st passage in cell culture • T/c • • • • • • A • • • • A/t • •
B156—serum (ex vivo) • T/C • • • • • A/g A/t • • • • T/a • •
B156—1st passage in cell culture • T/c • • • • • • A • • • • A • •
J6/JFH1ΔHVR1 Infected human liver chimeric mouse samples
K826R—plasma (ex vivo) • • • • G/t T • • • • • • • • • •
K826R—1st passage in cell culture • • • • G T • • • • • • • • • •
K890R—plasma (ex vivo) • • G/a G • • A • • • G • • • G/A G/A
K890R—1st passage in cell culture • • G G • • A • • • G • • • • •
B150R—plasma (ex vivo) A/c • • • • • • A/g • C/g • • • • • •
B150R—1st passage in cell culture C/A • • • • • • • • C/g • • • • • •
J6/JFH1A876P Infected human liver chimeric mouse samples
K1219RL—1st passage in cell culture • • • • • • • • • C • • • • • •
K1216L—1st passage in cell culture • • • • • • • • • C • • C/G • • •
K1207—1st passage in cell culture • • • • • • • • • C • G/c • • • •
J6/JFH1ΔHVR1/A876P Infected human liver chimeric mouse samples
B413L—1st passage in cell culture A/g • • • • • • • • C • • • • • •
B413RL—1st passage in cell culture • • • • G • • • • C • • • • • •
K1207R—1st passage in cell culture A/g • • T/g T/g • • • • C • • • • • •
K1207L—1st passage in cell culture • • • • G/t • • • • C • • • • • •
Amino acid number and type
J6/JFH1 position 78 94 434 447 730 871 872 875 875 880 904 1322 2243 2275 2350 2453
H77 abs. ref. (AF009606) 78 94 434 447* 726* 867 868 871 871 876 900 1318 2243 2275 2350 2431
Change relative to J6/JFH1 K→Q/E A→V H→R F→V L→V R→L G→D D→G D→E A→P Y→C C→W Q→H M→K K→R I→V
The entire open reading frame of viruses was sequenced. The cell culture viruses were sequenced at peak of infection. Only nucleotide changes resulting in amino acid changes are shown. Capital letters indicate the presence of one determinate sequence
peak. Two capital letters separated by a slash indicate the presence of a 50/50 quasispecies, whereas a capital letter separated by a slash from a lowercase letter indicates a quasispecies with a dominant versus a minor sequence. Light grey indicates
mutation cluster between amino acid positions 867–876. Dark grey indicates mutation introduced to the virus genome by cloning.
*Mutations F447V and L726V were generated for J6/JFH1 and J6/JFH1ΔHVR1 recombinant viruses and were found to have minor in vitro adaptive fitness effects for the hypervariable region 1 (HVR1)-deleted variant, but not for J6/JFH1, and to have no
effect on neutralisation susceptibility of J6/JFH1ΔHVR1 against H06 IgG.
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B156) and directly sequenced the entire genome ORF (table 1).
All viruses had developed dominant coding mutations within a
short region in or near the third putative transmembrane
domain of NS2: R867L, G868D, D871G, D871E or A876P
(positions relative to H77 reference strain, GenBank accession
number AF009606, table 1). We inoculated Huh7.5 cells with
plasma or serum from HCV-infected mice at the sequenced time-
point. The virus spread to >80% of cells in 8–11 days, and the
entire ORF was sequenced. We observed high correlation of
obtained sequences between in vivo and ex vivo samples (table 1).
In vivo derived NS2 mutations conferred increased
infectivity titres of J6/JFH1 in vitro by increasing assembly
and release
J6/JFH1 constructs generated with the identiﬁed R867L,
G868D, D871G, D871E or A876P substitutions, along with the
parental control J6/JFH1, were used to generate genomic HCV
RNA, which was transfected into Huh7.5 cells. All recombi-
nants infected >80% of the cells 72 h post transfection.
Analysing HCV infectivity titres in supernatants revealed that
the NS2 mutations increased titres by 5–10-fold (ﬁgure 2A).
Increased titres were conﬁrmed in a separate transfection (not
shown). As A876P displayed the most dramatic effect on infect-
ivity and appeared in vivo in the absence of envelope mutations
(table 1), we selected this mutant for further analysis. In a
similar transfection experiment, we found that A876P conferred
a 10-fold increase in infectivity titres for HVR1-deleted J6/
JFH1 (ﬁgure 2B). Using transfection supernatants, which had
been FFU titrated in triplicate, we performed controlled multi-
plicity of infection experiments and monitored infectivity titres
in resulting culture supernatants (ﬁgure 2C, D). For J6/JFH1,
we conﬁrmed that A876P and G871G/E increased viral
ﬁtness, whereas R867L and G868D had minor, if any, effect
compared to the original virus (ﬁgure 2C). The HVR1-deleted
J6/JFH1 with A876P had faster kinetics and a >10-fold increase
in infectivity titres (ﬁgure 2D). Direct sequencing of the HVR1
region and the N-terminal part of NS2 of viral RNA at peaks of
infection for the different recombinants conﬁrmed their viral
identity.
To evaluate which part of the viral life cycle was improved by
A876P, we performed transfection of HCV-entry-impaired
Huh7-derived S29 cells.26 Intracellular HCV Core values were
similar for J6/JFH1 and J6/JFH1ΔHVR1 with and without A876P,
suggesting that viral replication was unaltered (ﬁgure 3A).
However, intracellular infectivity was greatly increased for
viruses with A876P (ﬁgure 3B), indicating an increase in virus
assembly. We observed increased extracellular Core and infectiv-
ity titres (ﬁgure 3C, D), as well as increased speciﬁc infectivity,
for viruses with A876P, thus conﬁrming improved assembly as
well as either a direct or indirect effect on virus release.
Inoculations of human liver chimeric mice with
culture-derived J6/JFH1A876P and J6/JFH1ΔHVR1/A876P led to
high-titre infections
We generated virus stocks of J6/JFH1A876P and J6/JFH1ΔHVR1/
A876P by infecting naive Huh7.5 cells and veriﬁed the virus ORF
by direct sequencing. Subsequently, three and four mice were
inoculated with 104 FFU of culture-derived J6/JFH1A876P
(K1207, K1219RL and K1216L) or J6/JFH1ΔHVR1/A876P
(K1207R, K1207L, B413L and B413RL), respectively. All
animals became infected with HCV genome titres >105.6 IU/mL
during the ﬁrst four weeks (ﬁgure 1C, D).
We inoculated Huh7.5 cells with mouse plasma or serum-
derived HCV using animal samples from weeks 2 to 3 of infec-
tion. The viruses spread to >80% of cells in 6–8 days. Based on
our observation that in vivo derived J6/JFH1 (mJ6/JFH1) could
be cultured ex vivo without additional changes or reversions in
the HCV genome (see above), we sequenced the entire ORF of
viruses recovered from cell culture passages of either week 2 or
3 of the in vivo samples. In all ex vivo samples, the presence of
A876P was conﬁrmed and no additional NS2 mutations were
observed (table 1). In addition, the number of dominant or
Figure 2 In vitro viability of HCV recombinants J6/JFH1 and J6/JFH1ΔHVR1 harbouring in vivo derived mutations in NS2. (A and B) Huh7.5 cells were
transfected with HCV RNA of the indicated J6/JFH1-based recombinants and infectivity titres were determined days 1–4 post transfection. (C and D)
Huh7.5 cells were infected with HCV recombinants at a multiplicity of infection (MOI) of 0.003 from transfection supernatants of the indicated
J6/JFH1-based recombinants. Supernatants were taken every other day for infectivity titrations; cells were split 1–3. Values represent the mean of triplicate
titre determinations and error bars represent SD. FFU, focus forming units; GND, J6/JFH1 with GND polymerase substitutions (negative control).
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50/50 coding mutations in the genomes of passaged viruses was
4.7-fold lower compared with mice inoculated with J6/JFH1
viruses without the A876P mutation (2.8 vs 0.6 average coding
changes per genome).
Altered density of culture-derived J6/JFH1ΔHVR1 was not
observed for in vivo-derived viruses
We previously reported that the density of infectious
HVR1-deleted viruses of several HCV genotypes, including the
2a recombinant J6/JFH1ΔHVR1, changed from a 1.01 to 1.1 g/
mL range for the original recombinant to a single peak at
∼1.1 g/mL.25 We performed buoyant density gradient centrifu-
gations of J6/JFH1A876P and J6/JFH1ΔHVR1/A876P derived either
from cell culture or from pooled mouse samples. HCV RNA
distributions were similar in all cases (ﬁgure 4A, B). Comparing
the density of culture-derived infectious particles, we conﬁrmed
previous ﬁndings as J6/JFH1A876P had a heterogeneous density
from 1.02 to 1.1 g/mL, whereas J6/JFH1ΔHVR1/A876P displayed a
single high-titre infectivity peak at ∼1.1 g/mL (ﬁgure 4C).
However, in vivo derived mJ6/JFH1A876P and mJ6/JFH1ΔHVR1/
A876P displayed comparable density proﬁles ranging from 1.02
to ∼1.1 g/mL (ﬁgure 4D). We repeated this experiment using ex
vivo samples pooled from all sampled timepoints of the mouse
infections for in vivo derived J6/JFH1A876P with and without
HVR1, and conﬁrmed their heterogenous densities.
The HVR1 motif protected HCV from nAbs in H06 IgG both
in vitro and in vivo
We and others have previously demonstrated an increased neu-
tralisation sensitivity of HVR1-deleted viruses against chronic-
phase sera from HCV-infected patients.25 35 36 Using H06 IgG
puriﬁed from genotype 1a chronic-phase plasma (patient H), we
performed a dose–response in vitro neutralisation assay based
on FFU reduction for in vitro generated viruses J6/JFH1A876P
and J6/JFH1ΔHVR1/A876P. J6/JFH1ΔHVR1/A876P was highly neu-
tralisation sensitive with an IC50 value of 4.3×10
−4 mg/mL,
whereas J6/JFH1A876P could only be partially neutralised with
an estimated IC50 value of 1.1 mg/mL (ﬁgure 5A).
J6/JFH1A876P and J6/JFH1ΔHVR1/A876P were fully viable in
vivo (ﬁgure 1C, D and table 1) and displayed physiochemical
properties similar to that reported for in vivo-derived HCV
(ﬁgure 4), and we, therefore, used these viruses to evaluate
HVR1-mediated antibody protection in vivo. The mouse pools
used in these experiments were the same as the ones described
above to verify the heterogenous densities of mouse derived J6/
JFH1A876P virus with and without HVR1. We ascertained the
HCV envelope sequence of the pools by clonal analysis (9 or 10
clones for each pool) and subsequent validation of positions
with >20% sequence variation by direct sequencing. We did
not ﬁnd changes in the J6/JFH1A876P pool. However, we did
observe a dominant substitution N430D/n (A1629G/a) for
J6/JFH1ΔHVR1/A876P, which would abolish the N-linked
Figure 3 NS2 mutation A876P increased infectivity of HCV recombinants J6/JFH1 and J6/JFH1ΔHVR1 by increasing virus assembly and possibly
release. Entry-impaired S29 cells were transfected with HCV RNA of the indicated J6/JFH1-based recombinants. (A) Intracellular Core values were
determined in duplicate for 4 and 48 h post-transfection samples. Core values were normalised to the 4 h values as a marker of transfection
efﬁciency. (B) Infectious intracellular HCV was extracted by freeze/thawing and subsequent clearing by centrifugation. Infectivity titres were
determined in triplicate. (C) Extracellular Core values in duplicate and (D) extracellular infectivity titres in triplicate were measured directly on the
48 h cell culture supernatants. All bars in the different panels signify mean values with SDs. *Value below assay cut-off. FFU, focus forming units.
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glycosylation of N430. We generated an HVR1-deleted J6/JFH1
recombinant with this substitution that we passaged, sequence-
conﬁrmed in the envelope genes and tested in the in vitro neu-
tralisation assay using H06 IgG, and found no effect on neutral-
isation susceptibility (not shown). However, this was not
surprising as N430 is not a part of the HCV glycan shield.37
Human liver chimeric mice were loaded either with irrelevant
IgG or with H06 IgG, and 3 days later they were challenged
with either mJ6/JFH1A876P or mJ6/JFH1ΔHVR1/A876P derived
from pooled mouse samples (see above). All animals had plasma
levels of human albumin >2 mg/mL at the time of loading with
human IgG (indicating high-level liver humanisation). The infec-
tions were evaluated by measuring HCV RNA titres for 4 weeks
post virus inoculation. For mJ6/JFH1A876P, the H06 IgG con-
ferred only partial protection since all animals became infected,
albeit with ∼100-fold decreased HCV RNA titres (ﬁgure 5B), in
agreement with the partial neutralisation observed in vitro
(ﬁgure 5A). For mJ6/JFH1ΔHVR1/A876P, we observed complete
protection with no detectable viraemia in all three animals at all
timepoints (ﬁgure 5C), indicating that the protection from neu-
tralisation provided by HVR1 in vitro also occurred in vivo. We
determined the H06 human IgG plasma level at the time of
virus inoculation to be between 1.6 and 2.3 mg/mL. All animals
without detectable HCV RNA inoculated with mJ6/JFH1ΔHVR1/
A876P had human serum albumin levels >5 mg/mL at weeks 1
and 3 post challenge. Thus, failure of infection was not due to
graft failure, but due to efﬁcient heterologous neutralisation in
vivo. Interestingly, one of the H06 IgG inoculated animals
infected with mJ6/JFH1A876P displayed a rise in HCV RNA
titres at week 3. Upon sequencing HCV RNA extracted from
this timepoint, we identiﬁed the dominant substitution D476G
(A1768G) in hypervariable region 2 (HVR2) of E2. We gener-
ated a sequence conﬁrmed ﬁrst passage stock of this virus and
performed dose–response neutralisation experiments comparing
sensitivity against H06 IgG in vitro. We observed a 6.6-fold
decrease in sensitivity (table 2). In addition, when comparing
sensitivity against monoclonal nAbs, AR3A, AR4A and AR5A,
we observed 2.0–5.8-fold decreases in sensitivity (table 2).
Thus, it appeared that D476G was an in vivo escape mutation.
DISCUSSION
We identiﬁed mutations in NS2 that appeared critical for in vivo
infectivity of J6/JFH1-based HCV recombinants and showed
that the in vivo derived mutations increased virus titres in cell
culture. The most efﬁcient of the identiﬁed NS2 mutations,
A876P, increased assembly and possibly release, which makes
the virus more suited for cell culture applications requiring high
yield of particles, such as vaccines based on inactivated culture-
derived HCV. Furthermore, since the NS2-adapted virus
appeared to be genetically stable both in vitro and in vivo, this
provides a valuable tool for bridging HCV studies in cell culture
and animal models. Finally, using these viruses we found an
increased heterologous neutralisation susceptibility of
HVR1-deleted J6/JFH1A876P in vivo, thus supporting the feasi-
bility of developing antigens for generating cross-genotype pro-
tective vaccines.
Figure 4 Equilibrium buoyant density centrifugation of in vitro and in vivo derived J6/JFH1 HCV recombinants. The indicated virus from Huh7.5
cultures (A and C) or from mouse samples (B and D) were layered onto an iodixanol gradient. Following ultracentrifugation, a total of 11 fractions of
1 mL were collected from the bottom and density was calculated. HCV RNA titres (A and B) were determined singly for all fractions and infectivity
titres (C and D) were determined in triplicates. Error bars represent SD. Pool of mJ6/JFH1A876P consisted of mouse samples: K1219RL, week 1;
K1216L, week 2; K1207, week 2. Pool of mJ6/JFH1ΔHVR1/A876P consisted of mouse samples: B413L, weeks 1 and 2; B413RL, week 1; K1207R, weeks
1 and 4; K1207L, week 2. FFU, focus forming units.
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Sequence analysis of HCV from ﬁve human liver chimeric
mice (ﬁgure 1A, B) suggested that culture-derived J6/JFH1 and
J6/JFH1ΔHVR1 were not genetically stable in vivo (table 1). We
observed consistent clustering of mutations at conserved resi-
dues within positions 867–876 of NS2 (R867L, G868D,
D871G, D871E or A876P). Analysing J6/JFH1 recombinants
harbouring these mutations revealed that they appeared to
increase viral ﬁtness (ﬁgure 2); A876P had the highest effect,
yielding at least 10-fold higher titres. Single-cycle infections of
CD81-deﬁcient S29 cells showed that A876P increased assembly
and possibly release (ﬁgure 3), which ﬁts well with a previous
report concerning the role of this region within NS2.38 A876P
also increased in vivo genomic stability of both J6/JFH1 and J6/
JFH1ΔHVR1 (table 1). These ﬁndings indicate virus bottlenecking
of the original virus, which could result in lower HCV RNA
titres in infected animals or even failure of infection.
Furthermore, the increased release of particles in vitro caused
by A876P suggests that this virus is an improved candidate for
overcoming the inherent difﬁculties of making large quantities
of HCV for inactivated whole-virus vaccines.39 40
Having conﬁrmed the full viability, both in vitro and in vivo,
of J6/JFH1 viruses harbouring the NS2 mutation, A876P, we
analysed the physiochemical properties of in vivo derived mJ6/
JFH1A876P and mJ6/JFH1ΔHVR1/A876P. In two independent
experiments, we found that the high, homogenous density of
culture-derived HVR1-deleted viruses was not observed for in
vivo derived viruses (ﬁgure 4), as the density of viruses with and
without HVR1 fully resembled what has been described for
plasma-derived particles.14 41 Our ﬁnding differed from a recent
study reporting that in vivo generated Jc1 without HVR1,
another J6/JFH1 variant, maintained a homogenous high-
density proﬁle.42 However, in our study the unaltered density of
HVR1-deleted viruses meant that we could exclude that differ-
ences in neutralisation sensitivity of HVR1-deleted particles was
caused by altered physiochemical properties.
H06 IgG (from a genotype 1a-infected patient) had a partial
effect against the 2a virus mJ6/JFH1A876P in vivo as all animals
became infected with lower viral titres (ﬁgure 5B). These results
were in agreement with in vitro results (ﬁgure 5A) and corrob-
orate our previous in vivo ﬁndings that HCV is able to infect in
the presence of heterologous chronic-phase patient-derived IgG,
even though these contain high titres of cross-genotype reactive
polyclonal nAbs.22 However, the partial effect was signiﬁcant
(100-fold titre decreases) and in conjunction with recent ﬁnd-
ings that HCV protection in vitro from polyclonal IgG can be
overcome with monoclonal nAbs targeting critical epitopes,36
our data support the possibility that complete protection in vivo
can be achieved, even for hard-to-neutralise HCV strains, such
as J6,17 23 particularly if higher antibody titres not attainable
here were generated. Furthermore, H06 IgG protected the
animals from virus challenge (104 IU) of HVR1-deleted mJ6/
JFH1 in vivo with no detectable viremia (ﬁgure 5C), showing
that complete protection is possible with heterologous antibody
and indicating that HVR1 plays a major role in protection of
HCV in vivo from nAbs. A previous study showed protection of
human liver chimeric mice against J6/JFH1, but only with a low
challenge dose of 103 IUs and only when the virus was pre-
incubated with vaccine-induced antibody prior to virus chal-
lenge.39 The apparent exposition of cross-genotype reactive epi-
topes of an HVR1-deleted virus in vivo suggests that this would
be a superior antigen for inducing high titres of these potentially
Figure 5 Hypervariable region 1 (HVR1) protects J6/JFH1 from
neutralisation both in vitro and in vivo. (A) HCV recombinant J6/
JFH1A876P or J6/JFH1A876P/ΔHVR1 were incubated in four replicates for
each dilution step of a dilution series of IgG puriﬁed from
chronic-phase patient serum H06 along with eight replicates of virus
only. The virus and virus/antibody mixes were used to infect Huh7.5
cells and the number of focus forming units/well was visualised after
48 h infection by HCV-speciﬁc NS5A immunostaining and counted.
Data were normalised to virus only and error bars represent SD.
GraphPad Prism (V.4.03) was used to ﬁt dose–response curves to the
data points. (B and C) Human liver chimeric mice were loaded with
either irrelevant or H06 IgG prior to inoculation with in vivo derived
mJ6/JFH1A876P (B) or mJ6/JFH1A876P/ΔHVR1 (C). HCV RNA titres were
measured on mouse plasma samples at weeks 1–4. HCV RNA cut-off
was 750 IU/mL. Lines represent the geometric mean of HCV RNA
measurements.
Table 2 The mutation D476G occurred during H06 IgG treatment
in vivo and conferred antibody resistance against H06 IgG and three
monoclonal antibodies, AR3–5, in vitro.
Antibody
IC50 value (mg/mL)
J6/JFH1 J6/JFH1D476G Fold change
H06 IgG 1100 7300 6.6
AR3A 19 48 2.5
AR4A 7.4 43 5.8
AR5A 43 88 2.0
Dose–response neutralisation was performed as described using HCV with J6
envelope proteins with and without D476G. Dose–response curves were analysed
using GraphPad PRISM (V.4.03) as described in ‘Materials and Methods’.
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protective antibodies. Interestingly, we identiﬁed a putative
escape mutation, D476G, in HVR2 of E2 for an animal infected
with J6 retaining HVR1. When tested in vitro, this mutation
conferred 6.6-fold resistance against H06 IgG as well as 2.0–
5.8-fold resistance against monoclonal nAbs AR3A, AR4A and
AR5A. While mutations that alter HCV neutralisation sensitivity
have previously been described in HVR2,43 this is the ﬁrst
report of an induced escape mutation in vivo. It is, therefore,
tempting to speculate whether the described variability in
HVR2 could be protecting HCV by modulating nAb sensitivity
of the virus. This ﬁnding could inspire further studies on the
role of HVR2.
Since an IgG preparation from a genotype 1a-infected patient
had a greater effect against the HVR1-deleted virus of genotype
2a than it did against the parental genotype 2a virus retaining
HVR1, the epitope protection elicited by HVR1 must involve
cross-genotype conserved epitopes. We thus conﬁrmed our pre-
vious in vitro ﬁndings that HVR1 protects cross-genotype con-
served neutralisation epitopes,25 although it should be
recognised that the in vivo data are based on a single HCV
isolate. The mechanism of HVR1-mediated antibody protection
remains unclear. However, HVR1 could be obstructing accessi-
bility of neutralisation epitopes as suggested35 or could contain
neutralisation inhibitory epitopes.44 45 The latter cannot by
itself explain increased neutralisation sensitivity of
HVR1-deleted viruses as monoclonal nAbs also exhibit greater
effectiveness against the HVR1-deleted Jc1 virus.35
The progress in developing an effective HCV vaccine con-
tinues and should be viewed in the context of developments in
related ﬁelds. Thus, recent clinical trials using a tetravalent live
attenuated vaccine against dengue virus demonstrated efﬁcient,
although serotype-dependent, protection.46 While genetic het-
erogeneity of HCV is considerable, our in vivo data suggest that
a single cross-genotype reactive vaccine might be attainable, pos-
sibly negating the need for multivalent approaches and simplify-
ing the development of a vaccine. Furthermore, targeting a
cross-serotype conserved epitope for dengue virus was recently
accomplished by using unique nAbs identiﬁed in patients,47 thus
providing promise for the development of an improved vaccine
antigen. This was recently accomplished for respiratory syncytial
virus by engineering of an optimal, stabilised, vaccine antigen
that was shown to elicit protective antibody responses against
the virus in animal models.48 Our ﬁndings aid both in identify-
ing a possibly superior vaccine antigen, which exposes con-
served neutralisation epitopes in the absence of HVR1, while
also identifying mutations in NS2 that increase in vitro particle
release of relevance for generating sufﬁcient quantities of virus
for whole-virus vaccination trials. Thus, our study is highly rele-
vant for efforts to devise an optimal HCV vaccine antigen.
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